Roche Ibandronate I.V. Has Four Times Potency Of Fosamax, Firm Says

Roche's I.V. formulation of the Boehringer Mannheim osteoporosis therapy ibandronate is four times more potent than Merck's Fosamax (alendronate) and twice as potent as Procter & Gamble's Actonel (risedronate), the company said at a recent R&D media conference in Basel.